| アブストラクト | BACKGROUND: Anal fistula is a pathological connection between the anal canal and perianal skin, which most commonly develops from an infected anal crypt. While the majority of anal fistulas are idiopathic, they are also associated with Crohn's disease (CD) and other inflammatory conditions. The prevalence of anal fistula is estimated to be 1-2 per 10000 patients, but population-based studies on anal fistula epidemiology are limited and outdated. AIM: To assess the prevalence of anal fistula and relevant comorbidities, with and without CD in the United Kingdom and Europe. METHODS: A retrospective population-representative observational cohort study was performed in The Health Improvement Network (THIN), a United Kingdom primary care database. Mid-year point prevalence of anal fistula was calculated on the first of July for each year between 2014 and 2017. Estimates were calculated for anal fistula overall and by CD status and standardized to the United Kingdom and European population. Prevalence of relevant comorbidities including lymphogranuloma venereum, hidradenitis suppurativa, anal presentation of sexually transmitted diseases, diabetes mellitus, and radiation in the pelvic area was reported. RESULTS: The United Kingdom-standardized overall point prevalence of anal fistula was 1.80 (95%CI: 1.65-1.94) per 10000 patients in 2017, while the Europe standardized estimate was 1.83 (95%CI: 1.68-1.98) per 10000 patients. Both these standardized point prevalence estimates ranged from 1.89 to 2.36 between 2014-2016. The United Kingdom-standardized point prevalence of anal fistula without CD was 1.35 (95%CI: 1.23-1.48) per 10000 patients, while the Europe-standardized estimate was 1.39 (95%CI: 1.26-1.52) per 10000 patients. In contrast, the standardized point prevalence estimate of anal fistula with CD was lower for both United Kingdom and Europe (0.44; 95%CI United Kingdom: 0.37-0.52, 95%CI Europe: 0.37-0.51) per 10000 patients in 2017. In 2017, 19% of anal fistula patients without CD and 13% of anal fistula patients with CD had at least one relevant comorbidity. These results show that anal fistulas are infrequent in the general population. 24.5% of prevalent anal fistulas are associated with CD, but other potentially etiological comorbidities are rare. CONCLUSION: This real-world evidence study estimated the United Kingdom-standardized prevalence of anal fistula was 1.80 per 10000 patients in 2017. Approximately 25% of cases may be associated with CD, while other comorbidities are rare. |
|---|
| ジャーナル名 | World journal of clinical cases |
|---|
| Pubmed追加日 | 2019/8/17 |
|---|
| 投稿者 | Hokkanen, Suvi Rk; Boxall, Naomi; Khalid, Javaria Mona; Bennett, Dimitri; Patel, Haridarshan |
|---|
| 組織名 | Real World Evidence Solutions, IQVIA, London N19JY, United Kingdom.;Evidence and Value Generation, Global Medical Affairs, Takeda Pharmaceuticals;International Inc., London WC2B 4AE, United Kingdom.;Department of Epidemiology, Takeda Pharmaceuticals International Inc., Cambridge,;MA 02139, United States; Adjunct, Perelman School of Medicine, University of;Pennsylvania, Philadelphia, PA 19104, United States.;International Inc., Deerfield, IL 6001, United States. hari.patel@takeda.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31417925/ |
|---|
